Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen
The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
During 1985–1990 the U.S. National Cancer Institute (NCI) phased out its murine leukemia P388 anticancer drug screening program and developed as the replacement a new in vitro primary screen based upon a diverse panel of human tumor cell lines. For each substance tested, the screen generates a remarkably reproducible and characteristic profile of differential in vitro cellular sensitivity, or lack thereof, across the 60 different cell lines comprising the panel. Several investigational approaches to display, analysis, and interpretation of such profiles and databases, derived from the testing of tens of thousands of substances during the past 4–5 years since the NCI screen became fully operational, have been explored. A variety of useful, practical applications of the in vitro screen have become apparent. As these applications continue to evolve, they are proving to be complementary to diverse other anticancer screening and drug discovery strategies being developed or pursued elsewhere. Reviewed herein are some practical considerations and selected specific examples, particularly illustrating research applications of the NCI screen that may be more broadly applicable to the search for new anticancer drug development leads with novel profiles of antitumor activity and/or mechanisms of action. © 1995 Wiley‐Liss, Inc. This article is a US Government work and, as such, is in the public domain in the United States of America.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, in December 1992, MDA‐MB‐435 was added to the NCI‐60 cell line panel for use in anticancer drug screening, where it was initially described as a “breast” cancer cell line.17”
From Authentication of M14 melanoma cell line proves misidentification of MDA‐MB‐435 breast cancer cell line (2018) · cites this paper as [17]
Citations
Cites
New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening
Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., & Boyd, M. R. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.13.1107 · Cited by 9,766
Self-citationMonks, A., Scudiero, D., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Hose, C., Langley, J., Cronise, P., Vaigro-Wolff, A., et al. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.11.757 · Cited by 3,289
Self-citationA Human Cell Line From a Pleural Effusion Derived From a Breast Carcinoma 2
Soule, H. D., Vazquez, J., Long, A., Albert, S., & Brennan, M. (1973) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/51.5.1409 · Cited by 2,449
Establishment and characterization of a human prostatic carcinoma cell line (PC-3).
Kaighn, M. E., Ks, N., Ohnuki, Y., Lechner, J. F., & Jones, L. W. (1979) · PubMed · Cited by 2,121
Breast Tumor Cell Lines From Pleural Effusions2
Cailleau, R., Young, R., Olivé, M., & Reeves, W. J. (1974) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/53.3.661 · Cited by 1,015
Paull, K. D., Shoemaker, R. H., Hodes, L., Monks, A., Scudiero, D. A., Rubinstein, L., Plowman, J., & Boyd, M. R. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.14.1088 · Cited by 967
Self-citationRubinstein, L. V., Shoemaker, R. H., Paull, K. D., Simon, R. M., Tosini, S., Skehan, P., Scudiero, D. A., Monks, A., & Boyd, M. R. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.13.1113 · Cited by 927
Self-citationIsolation of a human prostate carcinoma cell line (DU 145)
Stone, K. R., Mickey, D. D., Wunderli, H., Mickey, G. H., & Paulson, D. F. (1978) · International Journal of Cancer · doi:10.1002/ijc.2910210305 · Cited by 926
Long-term human breast carcinoma cell lines of metastatic origin: Preliminary characterization
Cailleau, R., Olivé, M., & Cruciger, Q. V. J. (1978) · In Vitro · doi:10.1007/bf02616120 · Cited by 679
Establishment and characterization of a cell line of human breast carcinoma origin
Keydar, I., Chen, L., Karby, S., Weiss, F. R., Delarea, J., Radu, M., Chaitcik, S., & Brenner, H. J. (1979) · European Journal of Cancer (1965) · doi:10.1016/0014-2964(79)90139-7 · Cited by 650
Research works printed but not linked: 6
- Acton EM, 1992, Anticancer specificity of some ellipticinium salts against human brain tumors in vitro, Proc Am Assoc Cancer Res, 33, 488
- Boyd MR, 1986, Accomplishments in Oncology, Vol 1, Cancer Therapy: Where Do We Go From Here?, 68
- Boyd MR, 1989, Cancer: Principles and Practice of Oncology Updates, 1
- Buolamwini JK, 1994, Searching for new molecular targets for therapy of cancer and AIDS: Characterization by 2D protein gel electrophoresis, Proc Am Assoc Cancer Res, 35, 613
- Grever MR, 1994, Status of in vivo evaluations in the NCI anticancer drug discovery program, Proc Am Assoc Cancer Res, 35, 369
- Stinson SF, 1992, Morphologic and immunocytochemical characteristics of human tumor cell lines for use in an anticancer drug screen, Anticancer Res, 12, 1035
Cited by
The NCI60 human tumour cell line anticancer drug screen
Shoemaker, R. H. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1951 · Cited by 2,620
Proteasome inhibitors: a novel class of potent and effective antitumor agents.
Adams, J., Palombella, V. J., Sausville, E. A., Johnson, J. I., Destree, A. T., Lazarus, D. D., Maas, J., Pien, C. S., Prakash, S., & Elliott, P. J. (1999) · PubMed · Cited by 1,614
A gene expression database for the molecular pharmacology of cancer
Scherf, U., Ross, D. T., Waltham, M., Smith, L. H., Lee, J. K., Tanabe, L., Kohn, K. W., Reinhold, W. C., Myers, T. G., Andrews, D. T., et al. (2000) · Nature Genetics · doi:10.1038/73439 · Cited by 1,450
Isolation and Synthesis of Biologically Active Carbazole Alkaloids
Knölker, H., & Reddy, K. R. (2002) · Chemical Reviews · doi:10.1021/cr020059j · Cited by 1,416
Impact of Natural Products on Developing New Anti-Cancer Agents
Cragg, G. M., Grothaus, P. G., & Newman, D. J. (2009) · Chemical Reviews · doi:10.1021/cr900019j · Cited by 1,302
An Information-Intensive Approach to the Molecular Pharmacology of Cancer
Weinstein, J. N., Myers, T. G., O'Connor, P. M., Friend, S. H., Fornace, A. J., Kohn, K. W., Fojo, T., Bates, S. E., Rubinstein, L. V., Anderson, N. L., et al. (1997) · Science · doi:10.1126/science.275.5298.343 · Cited by 1,183
Self-citationNichols, J. W., & Bae, Y. H. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.057 · Cited by 834
Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme
Pommier, Y., Pourquier, P., Fan, Y., & Strumberg, D. (1998) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(98)00129-8 · Cited by 551
Modern Natural Products Drug Discovery and Its Relevance to Biodiversity Conservation
Kingston, D. G. I. (2011) · Journal of Natural Products · doi:10.1021/np100550t · Cited by 516
Mortimer, C. G., Wells, G., Crochard, J.-P., Stone, E. L., Bradshaw, T. D., Stevens, M. F. G., & Westwell, A. D. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm050942k · Cited by 475
Chromosome segregation and cancer: cutting through the mystery
Jallepalli, P. V., & Lengauer, C. (2001) · Nature Reviews Cancer · doi:10.1038/35101065 · Cited by 463
A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.
Aghajanian, C. A., Soignet, S. L., Dizon, D. S., Pien, C. S., Adams, J., Elliott, P. J., Sabbatini, P. J., Miller, V. A., Hensley, M. L., Pezzulli, S., et al. (2002) · PubMed · Cited by 482
Khan, I., Ibrar, A., Ahmed, W., & Saeed, A. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.10.084 · Cited by 428
Cao, X., Ding, L., Xie, Z.-Z., Yang, Y., Whiteman, M., Moore, P. K., & Bian, J.-S. (2019) · Antioxidants & Redox Signaling · doi:10.1089/ars.2017.7058 · Cited by 408
Adams, B. K., Ferstl, E. M., Davis, M. C., Herold, M., Kurtkaya, S., Camalier, R. F., Hollingshead, M. G., Kaur, G., Sausville, E. A., Rickles, F. R., et al. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.05.006 · Cited by 392
El‐Subbagh, H. I., Abu-Zaid, S. M., Mahran, M. A., Badria, F. A.-E., & Al-Obaid, A. M. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000038m · Cited by 386
MicroRNAs modulate the chemosensitivity of tumor cells
Blower, P. E., Chung, J.-H., Verducci, J. S., Lin, S., Park, J.-K., Dai, Z., Liu, C.-G., Schmittgen, T. D., Reinhold, W. C., Croce, C. M., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0573 · Cited by 364
Recent Developments in the Maytansinoid Antitumor Agents
Cassady, J. M., Chan, K. K., Floss, H. G., & Leistner, E. (2004) · CHEMICAL & PHARMACEUTICAL BULLETIN · doi:10.1248/cpb.52.1 · Cited by 342
Schultz, C., Link, A., Leost, M., Zaharevitz, D. W., Gussio, R., Sausville, E. A., Meijer, L., & Kunick, C. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm9900570 · Cited by 334
Shankavaram, U. T., Reinhold, W. C., Nishizuka, S., Major, S., Morita, D., Chary, K. K., Reimers, M. A., Scherf, U., Kahn, A., Dolginow, D., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0650 · Cited by 330
Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents.
Mooberry, S. L., Tien, G., Hernandez, A. H., Plubrukarn, A., & Davidson, B. S. (1999) · PubMed · Cited by 324
Computational illumination for high-speed in vitro Fourier ptychographic microscopy
Tian, L., Liu, Z., Yeh, L.-H., Chen, M., Zhong, J., & Waller, L. (2015) · Optica · doi:10.1364/optica.2.000904 · Cited by 317
Global Proteome Analysis of the NCI-60 Cell Line Panel
Gholami, A. M., Hahne, H., Wu, Z., Auer, F. J., Meng, C., Wilhelm, M., & Kuster, B. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.07.018 · Cited by 302
Cytotoxicity, antioxidant and anti-inflammatory activities of Curcumins I–III from Curcuma longa
Ramsewak, R. S., DeWitt, D. L., & Nair, M. G. (2000) · Phytomedicine · doi:10.1016/s0944-7113(00)80048-3 · Cited by 302
50 Years of Preclinical Anticancer Drug Screening: Empirical to Target-Driven Approaches
Suggitt, M., & Bibby, M. C. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.971.11.3 · Cited by 298
Havrylyuk, D., Zimenkovsky, B. S., Vasylenko, O., Zaprutko, L., Gzella, A. K., & Lesyk, R. (2008) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2008.09.032 · Cited by 296
Noolvi, M. N., Patel, H. M., Bhardwaj, V., & Chauhan, A. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.03.015 · Cited by 283
Selective cytotoxic activities of two novel synthetic drugs on human breast carcinoma MCF-7 cells.
Badisa, R. B., Darling‐Reed, S., Joseph, P., Cooperwood, J. S., Latinwo, L. M., & Goodman, C. B. (2009) · PubMed · Cited by 281
Anticancer activities of some newly synthesized pyridine, pyrane, and pyrimidine derivatives
Amr, A. E. E., Mohamed, A. M., Mohamed, S. F., Abdel‐Hafez, N. A., & Hammam, A. E.-F. G. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.04.045 · Cited by 274
Gurski, L. A., Jha, A. K., Zhang, C., Jia, X., & Farach-Carson, M. C. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.07.054 · Cited by 269
Skoufias, D. A., DeBonis, S., Saoudi, Y., Lebeau, L., Crevel, I., Cross, R., Wade, R. H., Hackney, D., & Kozielski, F. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m511735200 · Cited by 269
Overview of matrix metalloproteinase expression in cultured human cells
Giambernardi, T. A., Grant, G. M., Taylor, G. P., Hay, R. J., Maher, V. M., Mccormick, J. J., & Klebe, R. J. (1998) · Matrix Biology · doi:10.1016/s0945-053x(98)90019-1 · Cited by 258
Chemistry and Biology of Salicylihalamide A and Related Compounds
Yet, L. (2003) · Chemical Reviews · doi:10.1021/cr030035s · Cited by 254
Amundson, S. A., Do, K. T., Vinikoor, L. C., Lee, R. A., Koch-Paiz, C. A., Ahn, J., Reimers, M., Chen, Y., Scudiero, D. A., Weinstein, J. N., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2120 · Cited by 253
Synthesis, antitumor and antiviral properties of some 1,2,4-triazole derivatives
Al‐Soud, Y. A., Al‐Dweri, M. N., & Al-Masoudi, N. A. (2004) · Il Farmaco · doi:10.1016/j.farmac.2004.05.006 · Cited by 253
Rostom, S. A. F., Shalaby, M. A., & Demellawy, M. E. (2003) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2003.08.003 · Cited by 250
Synthesis and anticancer activity evaluation of 4-thiazolidinones containing benzothiazole moiety
Havrylyuk, D., Мосула, Л. М., Zimenkovsky, B. S., Vasylenko, O., Gzella, A. K., & Lesyk, R. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.08.008 · Cited by 249
Havrylyuk, D., Zimenkovsky, B. S., Vasylenko, O., Gzella, A. K., & Lesyk, R. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300789g · Cited by 249
MicroRNA expression profiles for the NCI-60 cancer cell panel
Blower, P. E., Verducci, J. S., Lin, S., Zhou, J., Chung, J.-H., Dai, Z., Liu, C.-G., Reinhold, W., Lorenzi, P. L., Kaldjian, E. P., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0009 · Cited by 248
Proteasome Inhibition: a New Strategy in Cancer Treatment
Adams, J., Palombella, V. J., & Elliott, P. J. (2000) · Investigational New Drugs · doi:10.1023/a:1006321828515 · Cited by 248
Rostom, S. A. F. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.06.020 · Cited by 243
Fitzsimmons, S. A., Workman, P., Grever, M., Paull, K., Camalier, R., & Lewis, A. D. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.5.259 · Cited by 232
Self-citationBradshaw, T. D., Wrigley, S., Shi, D.-F., Schultz, R. J., Paull, K. D., & Stevens, M. F. G. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.122 · Cited by 224
Self-citationCragg, G. M. L. (1998) · Medicinal Research Reviews · doi:10.1002/(sici)1098-1128(199809)18:5<315::aid-med3>3.0.co;2-w · Cited by 223
Abadi, A., Eissa, A. A. H. M., & Hassan, G. S. (2003) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.51.838 · Cited by 221
Girgis, A. S. (2008) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2008.03.013 · Cited by 219
Patra, B., Peng, C.-C., Liao, W.-H., Lee, C.-H., & Tung, Y.-C. (2016) · Scientific Reports · doi:10.1038/srep21061 · Cited by 215
DeBonis, S., Skoufias, D. A., Lebeau, L., Lopez, R., Robin, G., Margolis, R. L., Wade, R. H., & Kozielski, F. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1079.3.9 · Cited by 215
Synthesis of some novel benzoxazole derivatives as anticancer, anti-HIV-1 and antimicrobial agents
RIDA, S. M., Ashour, F. A., El-Hawash, S. A., El‐Semary, M. M., Badr, M. H., & Shalaby, M. A. (2005) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2005.03.023 · Cited by 215
Braulio Insuasty, O., Tigreros, A., Orozco, F., Jairo Quiroga, P., Abonía, R., Nogueras, M., Sánchez, A., & Cobo, J. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.06.013 · Cited by 212
The NCI In Vitro Anticancer Drug Discovery Screen
Boyd, M. R. (1997) · Anticancer Drug Development Guide · doi:10.1007/978-1-4615-8152-9_2 · Cited by 205
Self-citationNishizuka, S., Chen, S.-T., Gwadry, F. G., Alexander, J., Major, S. M., Scherf, U., Reinhold, W. C., Waltham, M. C., Charboneau, L., Young, L., et al. (2003) · PubMed · Cited by 202
Synthesis and properties of new substituted 1,2,4-triazoles: potential antitumor agents
Al‐Soud, Y. A., Al-Masoudi, N. A., & Ferwanah, A. S. (2003) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(03)00043-9 · Cited by 198
Gielen, M., Biesemans, M., de Vos, D., & Willem, R. (2000) · Journal of Inorganic Biochemistry · doi:10.1016/s0162-0134(99)00161-0 · Cited by 213
Giovannetti, E., Erozenci, A., Smit, J., Danesi, R., & Peters, G. J. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.03.010 · Cited by 192
Al-Rashood, S. T., Aboldahab, I. A., Nagi, M. N., Abouzeid, L. A., Abdel-Aziz, A. A. M., Abdel-hamide, S. G., Youssef, K. M., Al-Obaid, A. M., & El-Subbagh, H. I. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.08.030 · Cited by 191
Antineoplastic agents from natural sources: achievements and future directions
Cragg, G. M., & Newman, D. J. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.12.2783 · Cited by 190
Sun, J. D., Liu, Q., Wang, J., Ahluwalia, D., Ferraro, D., Wang, Y., Duan, J.-X., Ammons, W. S., Curd, J. G., Matteucci, M. D., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1980 · Cited by 190
Steroid glycosides from marine organisms
Ivanchina, N. V., Kicha, A. A., & Stonik, V. A. (2011) · Steroids · doi:10.1016/j.steroids.2010.12.011 · Cited by 182
Mimaki, Y., Kuroda, M., Kameyama, A., Sashida, Y., Hirano, T., Oka, K., Maekawa, R., Wada, T., Sugita, K., & Beutler, J. A. (1997) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(97)00071-1 · Cited by 175
Gawad, N. M. A., Georgey, H. H., Youssef, R. M., & El‐Sayed, N. A. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.10.008 · Cited by 172
Menicagli, R., Samaritani, S., Signore, G., Vaglini, F., & Via, L. D. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0495374 · Cited by 172
Thornburg, C. C., Britt, J. R., Evans, J. R., Akee, R. K., Whitt, J. A., Trinh, S. K., Harris, M. J., Thompson, J. R., Ewing, T. L., Shipley, S. M., et al. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00389 · Cited by 171
Martinez, E. J., Owa, T., Schreiber, S. L., & Corey, E. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3496 · Cited by 170
Pyrazoline bearing benzimidazoles: Search for anticancer agent
Shaharyar, M., Abdullah, M. M., Bakht, M. A., & Majeed, J. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2009.09.032 · Cited by 170
Bussey, K. J., Chin, K., Lababidi, S., Reimers, M., Reinhold, W. C., Kuo, W.-L., Gwadry, F., Ajay, Kouros-Mehr, H., Fridlyand, J., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0155 · Cited by 169
DNA fingerprinting of the NCI-60 cell line panel
Lorenzi, P. L., Reinhold, W. C., Varma, S., Hutchinson, A. A., Pommier, Y., Chanock, S. J., & Weinstein, J. N. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0921 · Cited by 166
Kohlhagen, G., Paull, K. D., Cushman, M., Nagafuji, P., & Pommier, Y. (1998) · Molecular Pharmacology · doi:10.1124/mol.54.1.50 · Cited by 165
Self-citationQuantitative structure–activity relationship (QSAR) studies as strategic approach in drug discovery
Patel, H., Noolvi, M. N., Sharma, P., Jaiswal, V., Bansal, S., Lohan, S., Suthar, S. K., Abbot, V., Dhiman, S. S., & Bhardwaj, V. (2014) · Medicinal Chemistry Research · doi:10.1007/s00044-014-1072-3 · Cited by 164
Congiu, C., Cocco, M. T., & Onnis, V. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.12.023 · Cited by 163
Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives
Gürsoy, E., & Ulusoy-Güzeldemirci, N. (2006) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2006.10.012 · Cited by 162
Synthesis of New Indeno[1,2-c]isoquinolines: Cytotoxic Non-Camptothecin Topoisomerase I Inhibitors
Cushman, M., Jayaraman, M., Vroman, J. A., Fukunaga, A. K., Fox, B. M., Kohlhagen, G., Strumberg, D., & Pommier, Y. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000029d · Cited by 162
Fan, Y., Shi, L. M., Kohn, K. W., Pommier, Y., & Weinstein, J. N. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm0005151 · Cited by 162
Constituents of Compositae plants
Ukiya, M., Akihisa, T., Tokuda, H., Suzuki, H., Mukainaka, T., Ichiishi, E., Yasukawa, K., Kasahara, Y., & Nishino, H. (2002) · Cancer Letters · doi:10.1016/s0304-3835(01)00769-8 · Cited by 161
Study on the potential anti-cancer activity of phosphonium and ammonium-based ionic liquids
Kumar, V., & Malhotra, S. V. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.06.086 · Cited by 157
Elicitation, a New Window into Plant Chemodiversity and Phytochemical Drug Discovery
Poulev, A., O'Neal, J. M., Logendra, S., Pouleva, R., Timeva, V., Garvey, A., Gleba, D., Jenkins, I. S., Halpern, B. T., Kneer, R., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm020359t · Cited by 157
Bano, S., Javed, K., Ahmad, S., Rathish, I. G., Singh, S., & Alam, M. S. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.08.015 · Cited by 156
Natural products as probes of cell biology: 20 years of didemnin research
Vera, M. D., & Joullié, M. M. (2002) · Medicinal Research Reviews · doi:10.1002/med.10003 · Cited by 153
New 5-substituted thiazolo[3,2-b][1,2,4]triazol-6-ones: Synthesis and anticancer evaluation
Lesyk, R., Vladzimirska, O., Holota, S. M., Zaprutko, L., & Gzella, A. K. (2007) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2006.12.006 · Cited by 153
Structure-Activity Relationships of Sesquiterpene Lactones
Schmidt, T. J. (2006) · Studies in natural products chemistry · doi:10.1016/s1572-5995(06)80030-x · Cited by 151
Sansalvamide: A new cytotoxic cyclic depsipeptide produced by a marine fungus of the genus Fusarium
Belofsky, G. N., Jensen, P. R., & Fenical, W. (1999) · Tetrahedron Letters · doi:10.1016/s0040-4039(99)00393-7 · Cited by 150
Boyd, M. R., Farina, C., Belfiore, P., Gagliardi, S., Kim, J. W., Hayakawa, Y., Beutler, J. A., McKee, T. C., Bowman, B. J., & Bowman, E. J. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29517-3 · Cited by 150
Self-citationNovel sulphonamide derivatives for the treatment of cancer
Owa, T., & Nagasu, T. (2000) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.10.11.1725 · Cited by 149
Synthesis of benzimidazoles bearing oxadiazole nucleus as anticancer agents
Rashid, M., Husain, A., & Mishra, R. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.04.027 · Cited by 147
Abou‐Seri, S. M., Eldehna, W. M., Ali, M. M., & Ella, D. A. A. E. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.10.053 · Cited by 148
Synthesis of new spiroindolinones incorporating a benzothiazole moiety as antioxidant agents
Karalı, N., Güzel-Akdemir, Ö., Özsoy, N., Özbey, S., & Salman, A. (2009) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2009.12.001 · Cited by 144
Discovery and Development of Antineoplastic Agents from Natural Sources
Suffness, M., Newman, D. J., & Snader, K. M. (1989) · Bioorganic marine chemistry · doi:10.1007/978-3-642-74560-7_6 · Cited by 147
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids
Malhotra, S. V., & Kumar, V. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.11.085 · Cited by 142
Ibrahim, D. A. (2009) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2009.01.003 · Cited by 141
Synthesis and primary cytotoxicity evaluation of new 5-benzylidene-2,4-thiazolidinedione derivatives
Patil, V., Tilekar, K. N., Mehendale-Munj, S., Mohan, R., & Ramaa, C. S. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.07.014 · Cited by 141
Rabow, A. A., Shoemaker, R. H., Sausville, E. A., & Covell, D. G. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010385b · Cited by 148
Synthesis of new conjugated coumarin–benzimidazole hybrids and their anticancer activity
Paul, K., Bindal, S., & Luxami, V. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.12.071 · Cited by 140
El-Seedi, H. R., Burman, R., Mansour, A., Turki, Z. A., Boulos, L., Gullbo, J., & Göransson, U. (2012) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2012.12.007 · Cited by 140
Synthesis of novel quinoline-2-one based chalcones of potential anti-tumor activity
Abonía, R., Insuasty, D., Castillo, J., Braulio Insuasty, O., Jairo Quiroga, P., Nogueras, M., & Cobo, J. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.08.039 · Cited by 140
Benzimidazole clubbed with triazolo-thiadiazoles and triazolo-thiadiazines: New anticancer agents
Husain, A., Rashid, M., Yar, M. S., Siddiqui, A. A., & Mishra, R. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.07.011 · Cited by 139
Semisynthesis and in vitro anticancer activities of andrographolide analogues
Jada, S. R., Subur, G. S., Matthews, C., Hamzah, A. S., Lajis, N. H., Saad, M. S., Stevens, M. F. G., & Stanslas, J. (2007) · Phytochemistry · doi:10.1016/j.phytochem.2006.11.031 · Cited by 138
Amin, K. M., Eissa, A. A. M., Abou‐Seri, S. M., Awadallah, F. M., & Hassan, G. S. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.12.004 · Cited by 142
Bioassays for Anticancer Activities
McCauley, J. I., Zivanovic, A., & Skropeta, D. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-577-4_14 · Cited by 135
Braulio Insuasty, O., Montoya, A. L., Becerra, D., Jairo Quiroga, P., Abonía, R., Robledo, S. M., Vélez, I. D., Upegui, Y., Nogueras, M., & Cobo, J. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.06.049 · Cited by 134
Benzothiazoles: Search for anticancer agents
Noolvi, M. N., Patel, H., & Kaur, M. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.05.028 · Cited by 133
Metadata
- Authors
- Boyd, M. R., & Paull, K. D.
- Affiliations
- Frederick National Laboratory for Cancer Research (US)
- National Cancer Institute (US)
- Corresponding author
- Boyd, Michael R.
- ORCID
- Boyd, Michael R.
- Venue
- Drug Development Research
- Publisher
- Wiley
- Published
- 1995-02
- Volume
- 34
- Issue
- 2
- Pages
- 91-109
- ISSN
- 0272-4391 (ISSN-L)
- 1098-2299
- OpenAlex
- W2118909720
- Cited by
- 1,572
- References
- 40
- Citations by year
- 2026: 28 · 2025: 57 · 2024: 79 · 2023: 58 · 2022: 68 · 2021: 81 · 2020: 74 · 2019: 51 · 2018: 58 · 2017: 39 · 2016: 56 · 2015: 61 · 2014: 78 · 2013: 84 · 2012: 79
- FWCI
- 30.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drug Development Research (publishedVersion, public-domain)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- anticancer drug discovery, human cancer cell lines, anticancer activity, lead compound identification, mechanism of action
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.